Experimental drug AMG 420 tested in Tough-to-Treat myeloma – early trial halted
NCT ID NCT03836053
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received the drug as a continuous 28-day IV infusion. The study aimed to find the safest dose and check for side effects, but it was terminated early. Results may help guide future research, but no conclusions about effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 420
What this could lead to
If successful, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This was a very early Phase 1 trial with only 23 participants, and it was terminated early. The drug may cause serious side effects like cytokine release syndrome, and it is unknown if it will work in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068, United States
-
Centre Hospitalier Universitaire Dinant Godinne - Universite Catholique de Louvain Namur
Yvoir, 5530, Belgium
-
Centres Hospitaliers Jolimont - Hopital de Jolimont
Haine Saint Paul - La Louviere, 7100, Belgium
-
Kantonsspital St Gallen
Sankt Gallen, 9007, Switzerland
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
National Hospital Organization Okayama Medical Center
Okayama, Okayama-ken, 701-1192, Japan
-
St Vincents Hospital Melbourne
Fitzroy, VIC, Victoria, 3065, Australia
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States